

## INVITATION

We are delighted to invite you to:

# JEMPERLI Dinner Symposium 2025

*Enhancing Outcomes in Advanced Endometrial Cancer with JEMPERLI Immuno-Chemo Combination Therapy*

With Prof Isabelle Ray-Coquard



4 September 2025 (Thursday)



6:30PM - 9:00PM



The Westin Singapore, Ballroom 2, Level 3  
12 Marina View, Asia Square Tower 2, S018961

*Parking is available at Asia Square Tower 2, with direct access to the Hotel via the Hotel lift on level 5*



Register now:



## Programme

6:30PM Registration

7:00PM Welcome Address

7:05PM Lecture

7:45PM Case Discussion

8:15PM Q&A

8:45PM Closing

## Keynote Speaker:

**Prof Isabelle Ray-Coquard**  
Oncologist, Centre Léon Bérard  
Professor of Medecine, Université Claude  
Bernard Lyon I

## Chairperson:

**A/Prof David Tan**  
Senior Consultant, Department of  
Haematology-Oncology, National University  
Cancer Institute, Singapore

CME points pending

Supported by:



**GSK**

## Keynote Speaker



### Prof Isabelle Ray-Coquard

Oncologist, Centre Léon Bérard  
Professor of Medecine,  
Université Claude Bernard Lyon I

Prof Ray-Coquard obtained her medical degree in 1997, specialising in oncology. In 2003, she received a PhD from the Université Claude Bernard for her research on the factors that determine medical practices in oncology. She also earned a Master's degree in medical economics in 1996 and in statistics in 1995.

From 2008 to 2013, she served as Chairman of the gynecologic group for clinical trials of the French National Cancer Institute (INCA). She is currently the Network Director of the national observatory dedicated to rare ovarian cancer ([www.ovaire-rare.org](http://www.ovaire-rare.org)), a network funded by the INCA commission and focused on the management of all rare gynaecological cancers.

At the Groupe d'investigateurs national evaluation des cancers de l'ovaire (GINECO), she has been active in the translational research advisory committee, the scientific committee, and has served as chairman of both the endometrial cancer subgroup and the rare tumours committee. Since 2002, she has also been developing translational research dedicated to ovarian cancer with INSERM within the Cancer Research Centre of Lyon (CRCL), directed by A. Puisieux on the CLB campus, and more specifically with Research Team 11 of CRCL.

From 2009 to 2016, she chaired the rare cancer working group of the Gynecologic Cancer InterGroup (GCIG), dedicated to clinical trials in all gynaecological cancers. She is currently the President of the GINECO group.

She is an active member of several professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC, the European Society of Medical Oncology, and the European Society of Gynaecological Oncology.

For Singapore Healthcare Professionals Only

For reporting of adverse events, please write to [sg.drugsafety@gsk.com](mailto:sg.drugsafety@gsk.com)

Full Prescribing Information is available on request.

Please read the full prescribing information prior to administration, available from GlaxoSmithKline Pte Ltd.

Trademarks are owned by or licensed to the GSK group of companies.

All images used in this material are for illustration purposes only.

GSK is not responsible for third party website content.

GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234, registered in Singapore No. 198102938K.

Tel: +65 6232 8338 Fax: +65 6291 9737

© 2025 GSK group of companies or its licensor

PM-SG-DST-LBND-250005 | July 2025



Scan here for JEMPERLI  
full Prescribing Information